Towards drug discovery for brain tumours: Interaction of kinins and tumours at the blood brain barrier interface

Recent Patents on CNS Drug Discovery

Volumn 6, Issue 1, 2011, Pages 31-40

  Harford Wright, Elizabeth ^a   Lewis, Kate M ^a   Vink, Robert ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Blood brain barrier; Bradykinin; CNS tumours; Glioma; Kinins; Substance P

Indexed keywords

BRADYKININ; KALLIKREIN; KININ DERIVATIVE; NEUROKININ; OPIATE AGONIST; SUBSTANCE P; TACHYKININ;

ANGIOGENESIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN TUMOR; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; GLIOMA; HUMAN; PATENT; PRIORITY JOURNAL;

ANGIOGENESIS MODULATING AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DISEASE PROGRESSION; DRUG DISCOVERY; HUMANS; KININS;

EID: 78650942039     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488911794079118     Document Type: Article

References (120)

1. World Health Organization. National Cancer Control Programmes: Policies and Managerial Guidelines. Geneva, Switzerland: World Health Organization 2002.
2. Bafaloukos D, Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev 2004; 30: 515-20.
3. Greenberg HS, Chandler WF, Sandler HM. Brain Tumours. New York: Oxford Univerity Press 1999.
4. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494-500.
5. Berk L. An overview of radiotherapy trials for the treatment of brain metastases. Oncology 1995; 9: 1205-12.
6. Ranjan T, Abrey LE. Current management of metastatic brain disease. Neurotherapeutics 2009; 6: 598-603.
7. Regina A, Demeule M, Laplante A, Jodoin J, Dagenais C, Berthelet F, et al. Multidrug resistance in brain tumors: Roles of the blood-brain barrier. Cancer Metastasis Rev 2001; 20: 13-25.
8. Twelves CJ, Souhami RL, Harper PG, Ash CM, Spiro SG, Earl HM, et al. The response of cerebral metastases in small cell lung cancer to systemic chemotherapy. Br J Cancer 1990; 61: 147-50.
9. Black KL, Ningaraj NS. Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control 2004; 11: 165-73.
10. Neuwelt EA, Barnett PA, McCormick CI, Remsen LG, Kroll RA, Sexton G. Differential permeability of a human brain tumor xenograft in the nude rat: Impact of tumor size and method of administration on optimizing delivery of biologically diverse agents. Clin Cancer Res 1998; 4: 1549-55.
11. Farkas A, Szatmari E, Orbok A, Wilhelm I, Wejksza K, Nagyoszi P, et al. Hyperosmotic mannitol induces Src kinase-dependent phosphorylation of beta-catenin in cerebral endothelial cells. J Neurosci Res 2005; 80: 855-61.
12. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Fiamengo SA, Neuwelt EA. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: A comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery 1998; 43: 879-86.
13. Ohnishi T, Sher PB, Posner JB, Shapiro WR. Capillary permeability factor secreted by malignant brain tumor. Role in peritumoral brain edema and possible mechanism for anti-edema effect of glucocorticoids. J Neurosurg 1990; 72: 245-51.
14. Heiss JD, Papavassiliou E, Merrill MJ, Nieman L, Knightly JJ, Walbridge S, et al. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 1996; 98: 1400-8.
15. Puduvalli VK. Brain metastases: Biology and the role of the brain microenvironment. Curr Oncol Rep 2001; 3: 467-75.
16. Thapar K, Rutka JT, Laws ER. Brain edema, Increased Intracranial Pressure, Vascular Effects, and other Epiphenomena of Human Brain Tumours. Brain Tumours: An Encyclopedic Approach. Edinburgh: Churchill Livingston 1995: 163-90.
17. Schackert G, Simmons RD, Buzbee TM, Hume DA, Fidler IJ. Macrophage infiltration into experimental brain metastases: Occurrence through an intact blood-brain barrier. J Natl Cancer Inst 1988; 80: 1027-34.
18. Strugar J, Rothbart D, Harrington W, Criscuolo GR. Vascular permeability factor in brain metastases: Correlation with vasogenic brain edema and tumor angiogenesis. J Neurosurg 1994; 81: 560-6.
19. Shibata S. Ultrastructure of capillary walls in human brain tumors. Acta Neuropathol 1989; 78: 561-71.
20. Hirano A, Matsui T. Vascular structures in brain tumors. Hum Pathol 1975; 6: 611-21.
21. Criscuolo GR. The genesis of peritumoral vasogenic brain edema and tumor cysts: A hypothetical role for tumor-derived vascular permeability factor. Yale J Biol Med 1993; 66: 277-314.
22. Zhang M, Olsson Y. Hematogenous metastases of the human brain-characteristics of peritumoral brain changes: A review. J Neurooncol 1997; 35: 81-9.
23. Zhang RD, Price JE, Fujimaki T, Bucana CD, Fidler IJ. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 1992; 141: 1115-24.
24. Long DM. Capillary ultrastructure in human metastatic brain tumors. J Neurosurg 1979; 51: 53-8.
25. Andrade SP, Beraldo WT. Pharmacological reactivity of neoplastic and non-neoplastic associated neovasculature to vasoconstrictors. Int J Exp Pathol 1998; 79: 425-32.
26. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000; 60: 4959-67.
27. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 2001; 89: 678-83.
28. Duchene J, Schanstra JP, Pecher C, Pizard A, Susini C, Esteve JP, et al. A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation. J Biol Chem 2002; 277: 40375-83.
29. Walker K, Perkins M, Dray A. Kinins and kinin receptors in the nervous system. Neurochem Int 1995; 26: 1-16.
30. Rodi D, Couture R, Ongali B, Simonato M. Targeting kinin receptors for the treatment of neurological diseases. Curr Pharm Des 2005; 11:1313-26.
31. Calixto JB, Medeiros R, Fernandes ES, Ferreira J, Cabrini DA, Campos MM. Kinin B1 receptors: Key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 2004; 143: 803-18.
32. Pereira MG, Gitai DL, Paco-Larson ML, Pesquero JB, Garcia-Cairasco N, Costa-Neto CM. Modulation of B1 and B2 kinin receptors expression levels in the hippocampus of rats after audiogenic kindling and with limbic recruitment, a model of temporal lobe epilepsy. Int Immunopharmacol 2008; 8: 200-5.
33. Francel PC. Bradykinin and neuronal injury. J Neurotrauma 1992; 9 (Suppl 1): S27-45.
34. Prat A, Biernacki K, Saroli T, Orav JE, Guttmann CR, Weiner HL, et al. Kinin B1 receptor expression on multiple sclerosis mononuclear cells: Correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. Arch Neurol 2005; 62: 795-800.
35. Hokfelt T, Pernow B, Wahren J. Substance P. A pioneer amongst neuropeptides. J Intern Med 2001; 249: 27-40.
36. Schaffer M, Beiter T, Becker HD, Hunt TK. Neuropeptides: Mediators of inflammation and tissue repair? Arch Surg 1998; 133: 1107-16.
37. Tsao P, Cao T, von Zastrow M. Role of endocytosis in mediating downregulation of G-protein-coupled receptors. Trends Pharmacol Sci 2001; 22: 91-6.
38. Cottrell GS, Padilla B, Pikios S, Roosterman D, Steinhoff M, Gehringer D, et al. Ubiquitin-dependent down-regulation of the neurokinin-1 receptor. J Biol Chem 2006; 281: 27773-83.
39. Harford-Wright E, Thornton E, Vink R. Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury. Neurosci Lett 2010; 481: 26-9.
40. Vink R, van den Heuvel C. Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury. Neurotherapeutics 2010; 7: 74-80.
41. Turner RJ, Blumbergs PC, Sims NR, Helps SC, Rodgers KM, Vink R. Increased substance P immunoreactivity and edema formation following reversible ischemic stroke. Acta Neurochir Suppl 2006; 96: 263-6.
42. Thornton E, Tran TT, Vink R. A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death. Neurosci Lett 2010; 481: 64-7.
43. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-5.
44. Katsu, Y.T., Kawai, M., Koike, H., Nukui, S. N-benzenesulfonyl L-proline compounds as bradykinin antagonists. US6734306 (2004).
45. Shaw, C.C., Hirst, D., Chen, T., O'rourke, M., Rao, P. Bradykinin B2 receptor antagonist peptide from amphibian skin. US20080044463 (2008).
46. Stewart, J.M.D., Chan, D.C., Whalley, E.T., Gera, L. Cytolytic bradykinin antagonists. US5849863 (1998).
47. Stewart, J.M.D., Gera, L. Bradykinin antagonists containing pentafluorophenylalanine. US5935932 (1999).
48. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 1998; 58: 4782-6.
49. Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: Functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004; 41: 265-312.
50. Li B, Goyal J, Dhar S, Dimri G, Evron E, Sukumar S, et al. CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res 2001; 61: 8014-21.
51. Golz, S.E., Bruggemeter, U., Geerts, A., Summer, H. Diagnostics and therapeutics for diseases associated with kallikrein 2 (KLK2). US20070218047 (2007).
52. Singh J, Naran A, Misso NL, Rigby PJ, Thompson PJ, Bhoola KD. Expression of kallikrein-related peptidases (KRP/hK5, 7, 6, 8) in subtypes of human lung carcinoma. Int Immunopharmacol 2008; 8: 300-6.
53. Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen-and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol 2008; 19: 1561-5.
54. Crivellari D, Pagani O, Veronesi A, Lombardi D, Nole F, Thurlimann B, et al. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001; 12: 353-6.
55. Hochstenbag MM, Twijnstra A, Wilmink JT, Wouters EF, ten Velde GP. Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol 2000; 48: 243-8.
56. Dong, Y.Q., Clements, J.A. Diagnosis of cancer or benign tumor using the aberrant expression product of the klk4 gene. US20040137455 (2004).
57. Yousef, G.S.J., Diamandis, E.P. Methods for detecting breast and ovarian cancer. US20060073525 (2006).
58. Mack, D.H.M.P., Gish, K.C., Afar, D. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer US20040029114 (2004).
59. Ladner, R.C., Ley, A.C., Hirani, S., Williams, A., Simoni, M.G., Bergamaschini, L. Kallikrein-inhibitor therapies. US7704949 (2010).
60. Esteban F, Munoz M, Gonzalez-Moles MA, Rosso M. A role for substance P in cancer promotion and progression: A mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev 2006; 25: 137-45.
61. Singh AS, Caplan A, Corcoran KE, Fernandez JS, Preziosi M, Rameshwar P. Oncogenic and metastatic properties of preprotachykinin-I and neurokinin-1 genes. Vascul Pharmacol 2006; 45: 235-42.
62. Lazarczyk M, Matyja E, Lipkowski A. Substance P and its receptors-a potential target for novel medicines in malignant brain tumour therapies (mini-review). Folia Neuropathol 2007; 45: 99-107.
63. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance-P receptors in human primary neoplasms: Tumoral and vascular localization. Int J Cancer 1995; 61: 786-92.
64. Ziche M, Morbidelli L, Pacini M, Geppetti P, Alessandri G, Maggi CA. Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res 1990; 40: 264-78.
65. Tung, J.S.B., Garofalo, A.W., Pleiss, M.A., Wu, J., Wone, D.W.G., Guinn, A.C., Dressen, D.B., Neitz, J.R., Marugg, J., Neitzel, M. Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists. US7432379 (2008).
66. Su, D., Bock, M.G. Novel quinoxalinone derivatives as bradykinin B1 antagonists. US20040132733 (2004).
67. Wu J, Akaike T, Hayashida K, Miyamoto Y, Nakagawa T, Miyakawa K, et al. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 2002; 98(1): 29-35.
68. Andoh T, Akira A, Saiki I, Kuraishi Y. Bradykinin increases the secretion and expression of endothelin-1 through kinin B2 receptors in melanoma cells. Peptides 2010; 31: 238-41.
69. Raidoo DM, Sawant S, Mahabeer R, Bhoola KD. Kinin receptors are expressed in human astrocytic tumour cells. Immunopharmacology 1999; 43: 255-63.
70. Lu DY, Leung YM, Huang SM, Wong KL. Bradykinin-induced cell migration and COX-2 production mediated by the bradykinin B1 receptor in glioma cells. J Cell Biochem 2010; 110: 141-50.
71. 2+ exchanger. J Neurosci 2007; 27: 13065-73.
72. Nantel, F.S., Chammas, R., Sirois, P., Battistini, B.J. Method of treating cancer and neuropathic complications induced by chemotherapeutic agents using selective Bradykinin B1 receptor antagonists. US20070015715 (2007).
73. Ikeda Y, Hayashi I, Kamoshita E, Yamazaki A, Endo H, Ishihara K, et al. Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res 2004; 64: 5178-85.
74. Luo W, Sharif TR, Sharif M. Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogenactivated protein kinase signaling pathway. Cancer Res 1996; 56: 4983-91.
75. Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, et al. Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest 2003; 83: 731-42.
76. Munoz M, Rosso M, Perez A, Covenas R, Rosso R, Zamarriego C, et al. The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 2005; 39: 427-32.
77. Burman, A.C.G., Prasad, S., Mukherjee, R., Jaggi, M., Singh, A.T. Substance P analogs for the treatment of cancer. US6596692 (2003).
78. Maier, N.C.I.P., Jarstfer, A.G. System and method for inhibiting cellular proliferation with tachykinins. US20107691817 (2010).
79. Akazawa T, Kwatra SG, Goldsmith LE, Richardson MD, Cox EA, Sampson JH, et al. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. J Neurochem 2009; 109: 1079-86.
80. Bigioni M, Benzo A, Irrissuto C, Maggi CA, Goso C. Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs 2005; 16: 1083-9.
81. Chan D, Gera L, Helfrich B, Helm K, Stewart J, Whalley E, et al. Novel bradykinin antagonist dimers for the treatment of human lung cancers. Immunopharmacology 1996; 33: 201-4.
82. Dunlop RJ, Campbell CW. Cytokines and advanced cancer. J Pain Symptom Manage 2000; 20: 214-32.
83. Palma C, Maggi CA. The role of tachykinins via NK1 receptors in progression of human gliomas. Life Sci 2000; 67: 985-1001.
84. Hu CP, Feng JT, Tang YL, Zhu JQ, Lin MJ, Yu ME. LIF upregulates expression of NK-1R in NHBE cells. Mediators Inflamm 2006; 2006: 84829.
85. Ribatti D, Conconi MT, Nussdorfer GG. Nonclassic endogenous novel regulators of angiogenesis. Pharmacol Rev 2007; 59: 185-205.
86. Stewart JM. Bradykinin antagonists as anti-cancer agents. Curr Pharm Des 2003; 9: 2036-42.
87. Ishihara K, Hayash I, Yamashina S, Majima M. A potential role of bradykinin in angiogenesis and growth of S-180 mouse tumors. Jpn J Pharmacol 2001; 87: 318-26.
88. Hu DE, Fan TP. [Leu8]des-Arg9-bradykinin inhibits the angiogenic effect of bradykinin and interleukin-1 in rats. Br J Pharmacol 1993; 109:14-7.
89. Holaday, J.W.B., Fortier, A.H. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers. US20036544947 (2003).
90. Chu, C., Shao, Z., Yang, Q., Huppe, G. Therapeutic uses of kallikreins. US20060287231 (2006).
91. Reulen HJ, Huber P, Ito U, Groger U. Peritumoral brain edema. A keynote address. Adv Neurol 1990; 52: 307-15.
92. Ng WH, Hy JW, Tan WL, Liew D, Lim T, Ang BT, et al. Aquaporin-4 expression is increased in edematous meningiomas. J Clin Neurosci 2009; 16: 441-3.
93. Saadoun S, Papadopoulos MC, Davies DC, Krishna S, Bell BA. Aquaporin-4 expression is increased in oedematous human brain tumours. J Neurol Neurosurg Psychiatry 2002; 72: 262-5.
94. Saadoun S, Papadopoulos M, Bell B, Krishna S, Davies D. The aquaporin-4 water channel and brain tumour oedema. J Anat 2002; 200: 528.
95. Hu J, Verkman AS. Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. FASEB J 2006; 20: 1892-4.
96. Papadopoulos MC, Saadoun S, Verkman AS. Aquaporins and cell migration. Pflugers Arch 2008; 456: 693-700.
97. Turner R, Vink R. Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke. Timely Top Med Cardiovasc Dis 2007; 11: E24.
98. Vink R, Young A, Bennett CJ, Hu X, Connor CO, Cernak I, et al. Neuropeptide release influences brain edema formation after diffuse traumatic brain injury. Acta Neurochir Suppl 2003; 86: 257-60.
99. Nimmo, A.J., Vink, R. Brain, spinal and nerve injury treatment. US20056841551 (2005).
100. Trabold R, Eros C, Zweckberger K, Relton J, Beck H, Nussberger J, et al. The role of bradykinin B(1) and B(2) receptors for secondary brain damage after traumatic brain injury in mice. J Cereb Blood Flow Metab 2010; 30:130-9.
101. Su J, Cui M, Tang Y, Zhou H, Liu L, Dong Q. Blockade of bradykinin B2 receptor more effectively reduces postischemic blood-brain barrier disruption and cytokines release than B1 receptor inhibition. Biochem Biophys Res Commun 2009; 388: 205-11.
102. Liu LB, Xue YX, Liu YH, Wang YB. Bradykinin increases blood-tumor barrier permeability by down-regulating the expression levels of ZO-1, occludin, and claudin-5 and rearranging actin cytoskeleton. J Neurosci Res 2008; 86: 1153-68.
103. Dodey, P.F., Luccarini, J., Martinez, J., Amblard, M., Daffix, I. Peptide agonists of bradykinin B2 receptor. US20016316413 (2001).
104. Black, K.L. Enhanced opening of abnormal brain tissue capillaries. US19966043223 (1996).
105. Malfroy-Camine, B. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability. US5112596 (1992).
106. Matsukado K, Inamura T, Nakano S, Fukui M, Bartus RT, Black KL. Enhanced tumor uptake of carboplatin and survival in gliomabearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 1996; 39: 125-33.
107. Zhao Y, Xue Y, Liu Y, Fu W, Jiang N, An P, et al. Study of correlation between expression of bradykinin B2 receptor and pathological grade in human gliomas. Br J Neurosurg 2005; 19: 322-6.
108. Nakano S, Matsukado K, Black KL. Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res 1996; 56: 4027-31.
109. Black KL, Yin D, Ong JM, Hu J, Konda BM, Wang X, et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res 2008; 1230: 290-302.
110. Hu J, Yuan X, Ko MK, Yin D, Sacapano MR, Wang X, et al. Calcium-activated potassium channels mediated blood-brain tumor barrier opening in a rat metastatic brain tumor model. Mol Cancer 2007; 6: 22.
111. Black, K.L. Enhanced opening of abnormal brain tissue capillaries. US20006043223 (2000).
112. Hu J, Ljubimova JY, Inoue S, Konda B, Patil R, Ding H, et al. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS One 2010; 5: e10108.
113. Black, K.L., Ningaraj, N.S. Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor. US20067018979 (2006).
114. Black, K.L, Ningaraj, N.S. Induction of apoptosis of malignant cells by activation of calcium-activated potassium channels. US20060280730 (2006).
115. Black, K.L., Wheeler, C. Use of minoxidil sulfate as an anti-tumor drug. US7705010 (2010).
116. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005; 46 (Suppl 1): 67S-75S.
117. Khan IU, Beck-Sickinger AG. Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals. Anticancer Agents Med Chem 2008; 8: 186-99.
118. Merlo, A.M., Macke, H., Reubi, J., Good, S. Radiopharmaceuticals for cancer diagnosis and treatment. US20070053837 (2007).
119. Cordier D, Forrer F, Kneifel S, Sailer M, Mariani L, Macke H, et al. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P-results from a phase I study. J Neurooncol 2010; 100: 129-36.
120. Schoor, O., Hilf, N., Weinschenk, T., Trautwein, C., Walter, S., Singh, H. Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers. EP2172211 (2010).